Business context and reporting period
Coya Therapeutics, Inc. filed this Form 8-K on October 5, 2026, reporting an update on its Phase 2/3 ALSTARS trial of COYA 302 for amyotrophic lateral sclerosis (ALS). The filing does not report a quarterly or annual financial period.
Key metrics
- The planned enrollment of 120 patients has been reached. Additional participants already in active screening may enroll if eligible.
- The randomized trial assigns participants 1:1:1 to one of two COYA 302 dosing regimens or placebo.
- The double-blind, placebo-controlled treatment phase lasts 24 weeks, followed by a 24-week blinded active-treatment extension for participants who complete the first phase.
- The primary endpoint is change from baseline to Week 24 in ALSFRS-R total score compared with placebo.
This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial results.
Material change and outlook
The reported milestone is completion of planned enrollment. Topline data from the double-blind treatment phase are anticipated in early Q2 2027; this timing is forward-looking and not assured.
Risks and contingencies
The filing cautions that trial timing, data availability, product-candidate safety and effectiveness, and other forward-looking expectations are subject to risks and uncertainties. It refers investors to the risk factors in the company’s 2025 Form 10-K and says it undertakes no obligation to update forward-looking statements except as required by law.
Important facts to verify
- Whether any additional participants in active screening are found eligible and enrolled.
- Whether topline results are announced in early Q2 2027 and what the efficacy and safety findings show.
- Trial progress and results for both COYA 302 dosing regimens, including the extension phase.